DIN 02530821 — NUCALA 40 MG
NUCALA is a solution of Mepolizumab marketed by GLAXOSMITHKLINE INC. The full Mepolizumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02530821
- Brand name
- NUCALA
- Active ingredient
- Mepolizumab
- Strength
- 40 MG
- Dosage form
- SOLUTION
- Route
- SUBCUTANEOUS
- Manufacturer
- GLAXOSMITHKLINE INC
- Health Canada status
- MARKETED
- Drug class
- Interleukin-5 (IL-5) inhibitor (monoclonal antibody)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Mepolizumab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02492989 | NUCALA | 100 MG | SOLUTION | GLAXOSMITHKLINE INC | MARKETED |
| 02492997 | NUCALA | 100 MG | SOLUTION | GLAXOSMITHKLINE INC | MARKETED |